The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart (Director Prof. Dr. M. Schwab) is operated by the Robert Bosch Foundation. Since its foundation in 1973, the institute has emerged as Germany's largest and most renowned research unit in the field of clinical pharmacology. Main research activities concentrate on the influence of genetic and non-genetic factors on the variability of drug efficacy and their contributions to disease development.

Research areas: Tumor biology, signaling pathway analysis, in vitro and ex vivo tumor models, tumor therapy

This project is part of a research group that seeks to identify new therapy options for lymphoma and lung cancer patients by bringing together refined molecular biological characterization of tumors and pre-clinical testing of innovative novel drugs.

The successful Ph.D. candidate will investigate innovative strategies for the therapy of pleural mesothelioma, an aggressive lung cancer with very limited therapeutic options.

The main topics of the project are:

• Molecular characterization of patient tumors towards the identification of suitable novel therapy targets
• Development of 3D mesothelioma models
• Pre-clinical efficacy and mechanism of action of promising novel drugs, in particular antibody drug conjugates

• Master’s degree in biology, molecular biology, technical biology, biochemistry, molecular medicine, or a related life sciences discipline; candidates who are about to obtain their degree are welcome to apply
• Strong interest in tumor biology and therapy
• Experimental background in molecular biology is preferred
• Experience in Western blot analysis, FACS and/or cell culture (human cells) is a plus

We offer ideal conditions for you to complete your doctoral degree:

• The Research Group PharmacoOmics & Lymphoma is embedded in the scientific environment of the Bosch Health Campus providing state-of-the-art research facilities and a highly integrative network of life science groups
• The Ph.D. candidate will participate in the structured program of the Ph.D. curriculum in cooperation with the University Tuebingen
• The position is for a fixed term of three years. Salary will be in line with 65% of pay group 13 of the Collective Agreement for the Public Service (TVöD).

The anticipated start date is January 1st, 2024.

Contact:

Dr. Claudia Kalla
[email protected]

A diverse and inclusive working environment with equal opportunities, in which everyone can realize their potential, is important to us.

We look forward to receiving your application. Complete applications in German or English, including a cover letter with a brief statement of research experiences and a CV. 

Sind Sie bereit für eine neue Herausforderung? Dann bewerben Sie sich jetzt über unser Online-Karriereportal.

Die angegebenen Arbeitgeberleistungen können je nach Position und Anstellungsverhältnis variieren.

Bitte beachten Sie die geltenden Nachweispflichten aufgrund des Infektionsschutzgesetzes als Einstellungsvoraussetzung.

Wir schätzen die Einzigartigkeit und Unterschiedlichkeit unserer Mitarbeitenden und fördern ein Arbeitsumfeld, das unabhängig von Alter, Geschlecht, sexueller Identität, Behinderung, Herkunft oder Religion gleiche Chancen ermöglicht. 

Mit Einreichung Ihrer Bewerbungsunterlagen stimmen Sie zu, dass Ihre Bewerberdaten in der Bewerbermanagementsoftware SmartRecruiters aufgenommen und verarbeitet werden. Hinweise zu unserem Datenschutz finden Sie hier: Datenschutz.